China
· Delayed Price · Currency is CNY Jointown Pharmaceutical Group Statistics
Total Valuation
Jointown Pharmaceutical Group has a market cap or net worth of CNY 26.87 billion. The enterprise value is 34.04 billion.
| Market Cap | 26.87B |
| Enterprise Value | 34.04B |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | Jun 7, 2024 |
Share Statistics
Jointown Pharmaceutical Group has 4.91 billion shares outstanding. The number of shares has decreased by -6.11% in one year.
| Shares Outstanding | 4.91B |
| Shares Change (YoY) | -6.11% |
| Shares Change (QoQ) | -5.04% |
| Owned by Insiders (%) | 2.82% |
| Owned by Institutions (%) | 13.89% |
| Float | 1.78B |
Valuation Ratios
The trailing PE ratio is 13.23 and the forward PE ratio is 11.67.
| PE Ratio | 13.23 |
| Forward PE | 11.67 |
| PS Ratio | 0.18 |
| PB Ratio | 1.06 |
| P/FCF Ratio | 326.61 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.21, with an EV/FCF ratio of 413.81.
| EV / Earnings | 16.70 |
| EV / Sales | 0.23 |
| EV / EBITDA | 7.21 |
| EV / EBIT | 8.54 |
| EV / FCF | 413.81 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.57.
| Current Ratio | 1.24 |
| Quick Ratio | 0.86 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 3.66 |
| Debt / FCF | 210.33 |
| Interest Coverage | 3.09 |
Financial Efficiency
Return on equity (ROE) is 7.12% and return on invested capital (ROIC) is 5.32%.
| Return on Equity (ROE) | 7.12% |
| Return on Assets (ROA) | 2.58% |
| Return on Capital (ROIC) | 5.32% |
| Revenue Per Employee | 4.92M |
| Profits Per Employee | 67,730 |
| Employee Count | 30,100 |
| Asset Turnover | 1.53 |
| Inventory Turnover | 7.79 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.02% in the last 52 weeks. The beta is 0.16, so Jointown Pharmaceutical Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -8.02% |
| 50-Day Moving Average | 4.77 |
| 200-Day Moving Average | 5.49 |
| Relative Strength Index (RSI) | 59.52 |
| Average Volume (20 Days) | 40,537,158 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Jointown Pharmaceutical Group had revenue of CNY 147.95 billion and earned 2.04 billion in profits. Earnings per share was 0.41.
| Revenue | 147.95B |
| Gross Profit | 11.44B |
| Operating Income | 3.98B |
| Pretax Income | 2.83B |
| Net Income | 2.04B |
| EBITDA | 4.62B |
| EBIT | 3.98B |
| Earnings Per Share (EPS) | 0.41 |
Balance Sheet
The company has 16.38 billion in cash and 17.30 billion in debt, giving a net cash position of -920.29 million or -0.19 per share.
| Cash & Cash Equivalents | 16.38B |
| Total Debt | 17.30B |
| Net Cash | -920.29M |
| Net Cash Per Share | -0.19 |
| Equity (Book Value) | 30.59B |
| Book Value Per Share | 5.17 |
| Working Capital | 15.74B |
Cash Flow
In the last 12 months, operating cash flow was 1.03 billion and capital expenditures -946.44 million, giving a free cash flow of 82.26 million.
| Operating Cash Flow | 1.03B |
| Capital Expenditures | -946.44M |
| Free Cash Flow | 82.26M |
| FCF Per Share | 0.02 |
Margins
Gross margin is 7.73%, with operating and profit margins of 2.69% and 1.38%.
| Gross Margin | 7.73% |
| Operating Margin | 2.69% |
| Pretax Margin | 1.91% |
| Profit Margin | 1.38% |
| EBITDA Margin | 3.12% |
| EBIT Margin | 2.69% |
| FCF Margin | 0.06% |
Dividends & Yields
This stock pays an annual dividend of 0.19, which amounts to a dividend yield of 3.60%.
| Dividend Per Share | 0.19 |
| Dividend Yield | 3.60% |
| Dividend Growth (YoY) | -9.70% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 85.12% |
| Buyback Yield | 6.11% |
| Shareholder Yield | 9.71% |
| Earnings Yield | 7.56% |
| FCF Yield | 0.31% |
Stock Splits
The last stock split was on June 7, 2024. It was a forward split with a ratio of 1.29.
| Last Split Date | Jun 7, 2024 |
| Split Type | Forward |
| Split Ratio | 1.29 |
Scores
Jointown Pharmaceutical Group has an Altman Z-Score of 2.28. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.28 |
| Piotroski F-Score | n/a |